Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance

Jefferson Russo Victor; Dong-Ho Nahm

doi:10.3389/fimmu.2023.1242860

. 2023 Nov 29;14:1242860. doi: 10.3389/fimmu.2023.1242860

Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance

Jefferson Russo Victor ^1,^2,^*,^†, Dong-Ho Nahm ^3,^*,^†

PMCID: PMC10716439 PMID: 38094290

Abstract

The regulatory T (Treg) cells constitute a functionally defined subpopulation of T cells that modulate the immune system and maintain immune tolerance through suppression of the development of autoimmune responses to self-antigens and allergic reactions to external antigens. Reduction in the number or function of Treg cells has been suggested as a key immune abnormality underlying the development of autoimmune and allergic diseases. In vitro studies have demonstrated that purified polyvalent immunoglobulin G (IgG) from multiple healthy blood donors can exert immunomodulatory effects on Treg cells. Incubation of polyvalent human IgG with purified CD4⁺CD25^high T cells increased the intracellular expression of interleukin (IL)-10. Intravenous administration of polyvalent human IgG induced significant expansions of CD4⁺ Foxp3⁺ Treg cells and clinical improvements in patients with autoimmune diseases. In human clinical trials, intramuscular administration of autologous total IgG significantly increased the percentage of IL-10-producing CD4⁺ Treg cells in the peripheral blood of healthy subjects and provided significant clinical improvements in patients with atopic dermatitis. These results suggest a clinical usefulness of polyvalent IgG-induced activation of Treg cells in human subjects. This review proposes a new hypothesis for immune tolerance mechanism by integrating the pre-existing “idiotypic network theory” and “Treg cell theory” into an “anti-idiotypic Treg cell theory.” Based on this hypothesis, an “active anti-idiotypic therapy” for allergic and autoimmune diseases using autologous polyvalent IgG (as immunizing antigens) is suggested as follows: (1) Intramuscular or subcutaneous administration of autologous polyvalent IgG produces numerous immunogenic peptides derived from idiotypes of autologous IgG through processing of dendritic cells, and these peptides activate anti-idiotypic Treg cells in the same subject. (2) Activated anti-idiotypic Treg cells secrete IL-10 and suppress Th2 cell response to allergens and autoimmune T cell response to self-antigens. (3) These events can induce a long-term clinical improvements in patients with allergic and autoimmune diseases. Further studies are needed to evaluate the detailed molecular mechanism underlying polyvalent IgG-induced Treg cell activation and the clinical usefulness of this immunomodulatory therapy for autoimmune and allergic diseases.

Keywords: immunoglobulins, T-lymphocytes, immunomodulation, regulatory T cell, atopic dermatitis, immune tolerance, allergic disease, autoimmune disease

1. Introduction

1.1. Immune tolerance and regulatory T cells

Immune tolerance is a state in which the immune system is unresponsive to foreign and self antigens that would otherwise result in a response (1). Immune tolerance is essential for maintaining immune homeostasis in healthy human subjects; defects in immune tolerance cause autoimmune and allergic diseases (1, 2).

Regulatory T (Treg) cells constitute a functionally defined subpopulation of T cells that modulate the immune system and have been suggested to play a central role in the maintenance of immune tolerance to self and foreign antigens through suppression of uncontrolled exaggerated autoimmune responses and allergic reactions that can be harmful to the host, thereby preventing the development of autoimmune and allergic diseases (1).

Treg cells are classified into natural Treg cells (nTreg cells) and induced Treg cells (iTreg cells) (3). nTreg cells arise from immature T cells in the thymus and express forkhead box P3 (Foxp3), CD4, and CD25 markers (4–6) and mediate peripheral immune tolerance through contact-dependent suppressor activity on other lymphocyte clones before they develop into full effector cells (7). iTreg cells develop after T cell maturation, do not express Foxp3, and can suppress other lymphocytes in peripheral tissues and lymph nodes but not through a contact-dependent mechanism; additionally, iTreg cells produce immunosuppressive cytokines (8). iTreg induction can be mediated through the exposure of naive CD4⁺ T cells to transforming growth factor-β (TGF-β), retinoic acid, and antigen presentation in peripheral tissues (3). In peripheral immune tolerance, repeated antigen exposure can also lead to the induction of iTregs (8). Among iTreg cells, the interleukin (IL)-10-producing CD4⁺ Treg cells (type 1 regulatory T cell: Tr1 cell) have been shown to play a key role in antigen-specific immune tolerance and can be induced through repeated administration of a specific antigen in humans (9–12). Foxp3⁺ Treg cells are primarily generated in the thymus (tTreg), but they can also be generated extrathymically at peripheral sites (pTreg) (13). Treg cells induce cytokine-dependent immune suppression through the secretion of IL-10 which suppresses Type 1 (Th1) and Type 2 T helper (Th2) cells (1, 2). Based on animal studies, decreased number and/or defective function (deficiency or dysfunction) of Treg cell have been suggested as a critical immune abnormality responsible for the development of autoimmune and allergic diseases (1, 2).

1.2. Polyvalent immunoglobulin G for immune regulation

Intravenous immunoglobulin G (IVIg), that is polyvalent IgG purified from the plasma pool of multiple healthy human blood donors, has been used to treat patients with primary immunodeficiency diseases associated with reduced immunoglobulin production (14, 15). Due to its immunomodulatory effects, IVIg has also been used to treat various autoimmune and allergic diseases (16, 17). Current evidence suggests that polyvalent IgG modulates the function of various immune cells, including dendritic cells (DCs), neutrophils, monocytes, macrophages, T cells, and B cells (18). Under in vitro experimental conditions, incubation of polyvalent human IgG with purified CD4⁺CD25^high T cells increased the expression of intracellular IL-10 in these cells (19). Activation of Treg cells seems to be the central mechanism responsible for the immunomodulatory and anti-inflammatory effects of polyvalent IgG (20–22).

The induction or activation of CD4⁺ Treg cells by IgG may involve diverse mechanisms considering the natural structure of these molecules. Some studies demonstrated that fragment crystallizable (Fc) regions of IgG obtained from IVIg formulations may interact with Fcγ receptors and thereby mediate part of the IVIg immunoregulatory effect (23, 24), while other report indicated that Fc fragments are not involved in this effect (25). Studies using recombinant IgG Fc fragments in murine models demonstrated a reduction in collagen-induced arthritis, idiopathic thrombocytopenic purpura, and myasthenia gravis (26–28), along with some beneficial effects in murine inflammatory neuropathy (29). The immunomodulatory effect of recombinant Fc fragments observed in the mouse model of collagen-induced arthritis could not be reproduced in macaques (28). In humans, the in vivo use of IVIg Fc fragments suggested a similar immunomodulatory effect of full IVIg in children with thrombocytopenic purpura (30); however, this effect could not be reproduced in ex vivo assays using human whole blood (31), and no other study could clarify the role of Fc fragments in human diseases (32).

The IgG fragments that can react with the antigen-binding sites (idiotypes) of pathogenic antibodies (IgG autoantibodies or IgE antibodies) in IVIg formulations have been suggested to mediate several aspects of immunomodulation through not only neutralization of pathogenic antibodies but also through other mechanisms, such as inhibition of complement activation and suppression of cytokine, in autoimmune and allergic diseases (33–35).

1.3. Idiotypic network theory

The “idiotypic network theory” that was initially proposed as a mechanism of immune tolerance by Jerne in 1974 suggests that the idiotypes of autologous immunoglobulins are immunogenic enough to induce immune responses (anti-idiotypic immune response) in the same host (36, 37). In this theory, the induction of an autoimmune anti-idiotypic response to the original idiotype plays a physiological role in the development of the immune tolerance state of the host. In this theory, immune tolerance is not a passive state of the immune system not responding to self and foreign antigens, but an active state of the immune system maintained through continuous low-grade physiological autoimmune responses to idiotypes of circulating autologous immunoglobulins in mammalian hosts preventing the development of exaggerated immune responses to self or foreign antigens (bacteria, virus, allergens) harmful to the host (36, 38, 39). Immune tolerance is a state of well-controlled responsiveness of the immune system to specific substances or tissues that would otherwise have the capacity to destroy these substances or tissues (36, 38, 39). Immune tolerance is induced via exposure to specific antigens through T cell receptors (TCRs) (1, 2). In the “idiotypic network theory”, idiotypes (variable regions with antigen specific binding capacity) of polyvalent autologous immunoglobulins and TCRs act as numerous endogenous antigens that can stimulate the immune system. These antigenic stimulations maintain numerous T cells and B cells with binding specificities to numerous antigens (both autoantigens and external antigens) and ultimately maintain an immune tolerance state (immune homeostasis).

This review focuses on mechanisms underlying the immunomodulation mediated by idiotypes of polyvalent IgG (including hypervariable regions of IgG) and not those mediated by the constant region of polyvalent IgG.

1.4. Anti-idiotypic regulatory T cell theory for immune tolerance

Unfortunately, knowledge regarding the scientific link between the pre-existing “Treg cell theory” and the “idiotypic network theory” for immune tolerance mechanisms is lacking. The mechanism underlying the cause-effect relationship between Treg cell activation and anti-idiotypic immune response has not been explained as yet. The disadvantages and weaknesses in the “idiotypic network theory” include the lack of experimental evidence regarding the actual mechanism in animals or humans through which immune tolerance is maintained and the absence of a human clinical trial demonstrating its clinical usefulness in treating autoimmune and allergic diseases. Rationale supporting the existence of “anti-idiotypic T cells” can be obtained from the “idiotypic network theory” itself. The “idiotypic network theory” suggests that the idiotypes of autologous immunoglobulins are immunogenic enough to induce immune responses (anti-idiotypic B cell and T cell immune response) in the same host (36, 37). Therefore, the pre-existence of anti-idiotypic T cells specifically recognizing peptides derived from idiotypes of autologous IgG is essential to maintain an immune tolerance state according to the “idiotypic network theory”. Thus, we propose a new hypothesis regarding the immune tolerance mechanism by integrating the “idiotypic network theory” and “Treg cell theory” into an “anti-idiotypic Treg cell theory” in this review.

T cells need antigenic stimulations for activation and survival (1, 3). What are the antigens stimulating Treg cells? This review proposes an answer that major antigens stimulating Treg cells include idiotypes (or its peptides processed by antigen-presenting cells, APCs) of autologous immunoglobulin.

2. Four hypothetical models for the mechanism underlying polyvalent IgG-induced activation of Treg cells

This review proposes four hypothetical models for the mechanism underlying polyvalent IgG-induced activation of Treg cells on the basis of previous studies and our speculations ( Figure 1 ).

Four hypothetical models explaining the mechanism underlying polyvalent IgG-induced activation of regulatory T cells. **(A)** Presentation of peptides from polyvalent IgG by APCs and differentiation of naive T cells into Treg cells; **(B)** presentation of peptide idiotypes of polyvalent IgG by APCs and activation of pre-existing resting anti-idiotypic Treg cells; **(C)** activation of resting Treg cells by direct binding of polyvalent IgG to TCRs or unidentified antigens; and **(D)** direct binding of polyvalent IgG to conserved receptors or other unidentified antigens on APCs and induction of the tolerogenic phenotype of APCs facilitating differentiation of naive T cells into Treg cells. IgG, immunoglobulin G; Treg, regulatory T cell; IL-10, interleukin-10; TCR, T-cell receptor; APC, antigen-presenting cell; MHC, major histocompatibility complex; DC, dendritic cell; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin.

[Model 1] Antigen presentation to naive T cells (Th0 cells): presentation of peptides from polyvalent IgG by APCs and differentiation of naive T cells into Treg cells ( Figure 1A ).

[Model 2] Antigen presentation to resting Treg cells: presentation of peptides from idiotypes of polyvalent IgG by APCs and activation of pre-existing resting anti-idiotypic Treg cells ( Figure 1B ).

[Model 3] Direct binding to antigens on T cells: activation of resting Treg cells by direct binding of polyvalent IgG to TCRs or unidentified antigens ( Figure 1C ).

[Model 4] Direct binding to antigens on APCs: direct binding of polyvalent IgG to conserved receptors or other unidentified antigens on APCs and induction of the tolerogenic phenotype of APCs facilitating differentiation of naive T cells into Treg cells ( Figure 1D ).

However, these four hypothetical models should be validated through future experiments. This review describes the limitations (unanswered questions) of these hypotheses to promote further studies on this topic by colleagues ( Table 1 ).

Table 1.

Six general questions on the mechanism of immune modulation and activation of regulatory T cells induced by polyvalent IgG.

Questions:

1) How can variable portions of polyvalent IgG (idiotopes or idiotype) induce activation of Treg cells?
2) Can anti-idiotypic T cells act as Treg cells?
3) What is the antigen-specificity of Treg cells activated by polyvalent IgG?
4) Which subpopulation of Treg cells is activated by polyvalent IgG (CD4⁺Foxp3⁺ Treg cells and/or CD4⁺Foxp3^-IL-10⁺ Treg cells)
5) Is the anti-idiotypic Treg cell-mediated immunomodulation a physiological mechanism working in healthy human subjects to maintain immune tolerance?
6) Could immunization with autologous polyvalent IgG trigger the activation of anti-idiotypic Treg cells, leading to a long-term clinical remission in patients with autoimmune and allergic diseases through the induction of immune tolerance?

Open in a new tab

IgG, immunoglobulin G; Treg cell, regulatory T cell; Foxp3, forkhead box P3; IL, interleukin.

2.1. Hypothetical model 1 and 2: activation of Treg cells by peptides from polyvalent IgG processed by APCs (main hypotheses of authors)

APCs, including DCs, take up antigens in peripheral tissues, process them into peptides through proteolysis, and load these peptides on major histocompatibility complex (MHC) class I and II molecules (40). This review suggests that APCs, including DCs, can phagocytose polyvalent IgGs and present the peptides to naive T cells, after which the naive T cells differentiate into Treg cells [Model 1], or polyvalent IgG derived peptides activate resting anti-idiotypic Treg cells to produce IL-10 [Model 2] ( Figures 1A, B ). The following are past studies supporting these two hypothetical models.

In an abortion-prone mouse model, peptides produced by APCs from processing of the constant region of polyvalent IgG with a high affinity to MHC class II molecules (that can activate Treg cells and are termed as Tregitopes) can reduce the fetal death rate and increase IL-10 producing CD4⁺CD25⁺Foxp3⁺ Treg cells (41). In a mouse model of ovalbumin (OVA)-induced asthma, intraperitoneal administration of IVIg from healthy human blood donors could induce antigen-specific peripherally generated Foxp3⁺ Treg cells even after selective depletion of pre-existing CD4⁺CD25⁺Foxp3⁺ Treg cells and inhibit Th2 responses and airway inflammation (42). Subsequently, the same research group demonstrated that the inhibitory effect of Tregitopes could promote tolerance by activating Treg activity in a mouse model of OVA-induced asthma (43). These results suggested that Tregitopes could be active components mediating IVIg-induced anti-inflammatory effect (Model 1, Figure 1A ).

In a murine model of OVA-immunization to induce OVA-specific IgG antibodies, subcutaneous injections of IVIg induced the activation and expansion of B and CD4⁺ T cells in the spleen and draining lymph nodes, resulted in a reduction in OVA-specific antibody production, and induced anti-IVIg IgG antibodies that mainly recognized the F(ab’)₂ fragments of IVIg (44). These immunomodulatory effects could not be induced after subcutaneous injections of two human IgG monoclonal antibodies that share the constant region of IgG but not their idiotypes (44). These observations suggested that the immune responses to idiotypes of IVIg with enormous sequence diversity might produce immunomodulatory effects suppressing the production of anti-OVA IgG antibodies (44). However, in this mouse model, there was no evidence of the activation of Treg cells induced through the subcutaneous injections of IVIg (44). Investigation of the human leukocyte antigen (HLA) class II peptide repertoire from IVIg-loaded human DCs via MHC-associated peptide proteomics (MAPPs) revealed that numerous peptides derived from the hypervariable region of IgG were strongly presented (45). Surprisingly, Tregitopes derived from the constant region of IgG failed to suppress effector immune responses against a specific antigen in both human peripheral blood mononuclear cells and mouse immune cells (45). These results suggested that the immunomodulatory effects of polyvalent IgG were originated from the hypervariable region (idiotype) of IgG and not from the constant region of IgG (Tregiotopes) (Model 2, Figure 1B ).

In humans, an author of this review (Nahm DH) reported that the intramuscular administration of autologous total IgG increased the percentage of IL-10-producing CD4⁺ T cells in the peripheral blood in 13 healthy human subjects (46). However, this report could not provide a detailed molecular mechanism underlying the autologous polyvalent IgG-mediated immunomodulation or the subpopulation of Treg cells activated by autologous polyvalent IgG.

This review provides a summary of results (subpopulation of Treg cells and mechanism) on the polyvalent IgG-induced activation of Treg cells from mouse studies (21, 42, 44, 47–51) ( Table 2 ). Further studies are needed to evaluate the characteristics of polyvalent IgG-derived peptides activating Treg cells and subpopulations of Treg cells mediating polyvalent IgG-induced immunomodulation.

Table 2.

Effect of polyvalent IgG-induced regulatory T cell activation in mouse model.

Induced disease	lineage	IgG type	Administration dose (route)	Evaluation timing	Specimen source	Measurement of Treg cell	Immunological effect (or mechanism)	Ref
Experimental autoimmune encephalomyelitis (EAE)	Mouse C57BL/6J female	Human IVIg	0.8 g/kg (IP)	Day 21	Spleen	↑ CD4⁺CD25⁺Foxp3⁺	Protection by IVIg was associated with an increase in CD4⁺CD25⁺Foxp3⁺ Treg cell numbers and function. IVIg failed to protect against EAE in Treg cell-depleted mice. IVIg had a direct effect on the proliferation of natural Treg cells.	(21)
OVA-induced airway hyperresponsiveness (AHR)	Mouse C57BL/6 male and female	Human IVIg	2 g/kg (day 28) (IP)	Day 32	Lung	↑ CD4⁺CD25^high Foxp3⁺	IVIg generated a de novo population of peripheral Treg (pTreg) cells in the absence of endogenous Treg cells. IVIg-generated pTreg cells were sufficient for inhibiting OVA-induced AHR. Adoptive transfer of purified IVIg-generated pTreg prior to antigen challenge effectively prevented airway inflammation and AHR in an antigen-specific manner.	(42)
OVA-induced IgE response	Mouse C57Bl/6NCrl female	Human IVIg	1mg, 10mg, 20mg, 50mg (day 0, day7, and day 14) (SC)	Day 15	Spleen LN	No difference of percentage CD4⁺CD25⁺ Foxp3⁺ between IVIg treatment group and control group	IVIg induced the activation and expansion of B and CD4⁺ T cells, reduced development of OVA-specific antibody, and induced anti-IVIg IgG antibodies that mainly recognizing the F(ab’)₂ fragments of IVIg.	(44)
OVA-induced IgE response	Mouse BALB/c male and female	OVA-immunized mouse IgG	600 ug/per pregnant mice at prenatal period (divided in 3 days at days 10,15 and 20) (IV)	Day 20	Spleen	↑ L-10-producing CD4⁺	Passive transfer of OVA-immunized IgG to pregnant mice increased the frequency of IL-10-producing T cells in offspring and prevented neonatal OVA-sensitization.	(47)
Collagen-induced arthritis (CIA)	Mouse DBA1/J male	Human IVIg	25 mg/mouse at day 7 (IV)	Week 15	Spleen	↑ CD4⁺CD25⁺ Foxp3⁺(FACS) ↑ CD4⁺CD25⁺ Foxp3⁺IL-10⁺ (confocal microscopy)	IVIg increased the number of Foxp3⁺ Treg cells. The therapeutic effects of IVIg are dependent on IL-10. The treatment effects of IVIG on arthritis were lost in IL-10-knockout mice.	(48)
Herpes simplex virus (HSV) induced fatal encephalitis	Mouse 129S6 male	Human IVIg	3.75 mg/mouse (IP)	Day 1 after HSV infection	Spleen	↑ CD4⁺CD25⁺Foxp3⁺	IVIg induced secretion of IL-10 from Treg cells and it produced anti-inflammatory effects that protect against fatal HSV encephalitis.	(49)
OVA-induced airway hyperresponsiveness (AHR)	Mouse C57BL/6	Human IVIg	2 g/kg 24hr before antigen challenge (day 28)(IP)	After 5 days of OVA or sham challenge	Spleen LN Lung	↑ CD4⁺Foxp3⁺	IVIg induced antigen-specific Foxp3⁺ Treg cells from non-Treg cell precursors. Induction of Treg cells was mediated by tolerogenic dendritic cells.	(50)
Experimental autoimmune encephalomyelitis (EAE)	Mouse C57BL/6J female	Human IVIg	0.8 g/kg/daily from day 0 to day 18 (IP)	Day 9	Spleen	↑ CD4⁺Foxp3⁺	IVIg inhibits the differentiation of naive CD4 T cells into EAE Th1/17 cells and induced an expansion of Foxp3⁺ Treg cells. F(ab’)₂ fragments retained this function of IVIg.	(51)

Open in a new tab

IgG, immunoglobulin G; IgE, immunoglobulin E; Treg cell, regulatory T cell; IVIg, purified polyvalent IgG from the plasma pool of multiple healthy human blood donors; Foxp3, forkhead box P3; OVA, ovalbumin; SC, subcutaneous; IP, Intraperitoneal; IV, intravenous; LN, lymph node; IL, interleukin; FC, fragment crystallizable.

2.2. Hypothetical model 3 and 4: activation of Treg cells by direct binding of polyvalent IgG to surface receptors on T cells or APCs

Addition of polyvalent human IgG to purified CD4⁺CD25^high T cells from healthy human subjects increased intracellular expression of IL-10 in CD4⁺CD25^high T cells under experimental cell culture conditions; this observation indicated a direct activation of Treg cells by polyvalent IgG (20). To explain the mechanism underlying polyvalent IgG induced direct activation of T cells, the “hook without bait theory” has been proposed by an author of this review (Victor JR) (52). In this theory, direct binding of idiotype of polyvalent IgG to the TCRs or unidentified antigens on the surface of CD4⁺ cells can induce differentiation of Treg cells from naive T cells or activate pre-existing Treg cells to secrete IL-10 ( Figure 1C ). The direct interaction between polyvalent IgG and antigens on the cell membrane of CD4⁺ thymic T cells induced cytokine production from CD4⁺ thymic T cells (53). However, this study did not evaluate the activation of Treg cells by direct binding of polyvalent IgG to antigens on the cell membrane of T cells. In a co-culture model of human DCs and CD4⁺ T cells as well as in a mouse model of experimental autoimmune encephalomyelitis, IVIg was seen to increases Treg cells through the binding of F(ab′)₂ fragments of IVIg with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) on DCs (54) ( Figure 1D ). A similar approach demonstrated that polyvalent IgG can specifically interact with murine DC immunoreceptors, favoring the induction of Treg cells (55). Another possibility is the direct binding of polyvalent IgG to an unidentified antigen (or conserved receptor) on the surface of APCs, and this interaction induces the changes of APCs into tolerogenic APCs, promoting the differentiation of naive CD4⁺ T cells into Treg cells and secretion of IL-10 ( Figure 1D ).

However, further studies are needed to validate these four hypothetical models of polyvalent IgG-induced Treg cell activation and the subpopulations of Treg cells (CD4⁺Foxp3⁺ T cells and/or Tr1 cells) involved in these processes.

3. Evidence supporting activation of Treg cells by polyvalent IgG in clinical trials

3.1. Evidence supporting activation of Treg cells upon intravenous administration of IVIg in human clinical trials

IVIg has been used as a replacement or immunomodulatory therapy in primary immunodeficiency, secondary immunodeficiency, hematological diseases, neuroimmunological diseases, rheumatic diseases, dermatological diseases, and other conditions including miscarriages (56). Clinical studies on IVIg therapy in primary immunodeficiency patients (57), the treatment of autoimmune rheumatic disease (58), Guillain-Barré syndrome (59), eosinophilic granulomatosis (60), Kawasaki disease (61), recurrent miscarriage (62), and repeated implantation failure (63) showed that IVIg therapy increased the percentage of Treg cells (mainly CD4⁺ Foxp3⁺ Treg cells) in the peripheral blood ( Table 3 ). In a clinical trial, IVIg therapy in patients with common variable immunodeficiency significantly increased the number of peripheral Treg cells (expressing CD4, CD25, and low levels of CD127) and plasma levels of IL-10 within 30 minutes after the infusion of IVIg, suggesting a highly efficient interaction between polyvalent IgG and Treg cells (64). This review provides a summary of study results (subpopulation of Treg cells and mechanism) on the polyvalent IgG-induced activation of Treg cells in human clinical trials ( Table 3 ) (46, 57–65).

Table 3.

Effect of polyvalent IgG-induced regulatory T cell in human clinical trials.

Treatment-target diseases	Study design	IgG type	Administration dose (route)	Evaluation timing	Measurementof Treg cell	Immunological effect (or mechanism)	Ref
Primary immunodeficiency	Prospective uncontrolled	IVIg	0.36-0.72 g/Kg for 1 day (IV)	Pre-infusion vs. 7 days after infusion	↑ CD3⁺CD4⁺CD25^High Foxp3⁺	Anti-inflammatory effects of IVIg inducing expansion of Treg cells was noticed as early as day 7.	(57)
Autoimmune rheumatic disease	Prospective uncontrolled	IVIg	2 g/Kg (IV)	Pre-infusion vs. 72 to 96 hour after last infusion	↑ CD4⁺CD25^high	Anti-inflammatory effects of IVIg with enhancement of Treg cells were observed.	(58)
Guillain-Barré syndrome	Prospective controlled	IVIg	0.4 g/Kg/daily for 4 days (IV)	Pre-infusion (0 week) vs. 1 week after infusion	↑ CD4⁺Foxp3⁺	IVIg reduced the frequency of Th1 and Th17 cells and expanded Treg cells. IVIg-expanded Treg cells exhibited T cell suppressive function.	(59)
Eosinophilic Granulomatosis	Prospective controlled	IVIg	0.4 g/kg/daily for 5 days (IV)	IVIg vs. without IVIg (3, 6, 12 and 24 months after infusion)	↑ CD25⁺ among CD4⁺	The frequency of CD25⁺ cells among CD4⁺ T cells increased significantly after IVIg treatment.	(60)
Kawasaki disease	Prospective controlled	IVIg	2 g/kg (IV)	Pre-infusion vs.48 hour after infusion	↑ CD4⁺CD25⁺ Foxp3⁺	Percentage of CD4⁺CD25⁺Foxp3⁺ cells were significantly increased at 48 hour after IVIg.	(61)
Recurrent miscarriage	Prospective controlled	IVIg	0.4 g/kg every 4 weeks during 32 weeks of gestation (IV)	At the diagnosis of first positive pregnancy vs. at week 32 (last infusion of IVIg)	↑ CD4⁺CD25⁺ CD127⁻	IVIg induced a significant increase of Treg cells.	(62)
Repeated implantation failure	Prospective controlled	IVIg	0.4 g/kg (2 days before embryo transfer) (IV)	2 days before embryo transfer vs. 15 days after embryo transfer	↑ CD4⁺ Foxp3⁺ CD127^−/low	IVIg induced a significant increase of Treg cells.	(63)
Common variable immunodeficiency	Prospective controlled	IVIg	0.3 g/kg by slow 2- hour (IV)	30 minutes before infusion vs.30 minutes after infusion	↑ CD4⁺ ↑ CD4⁺CD25⁺ CD127^−/low	IVIg increased percentage of Treg cells as early as at 30 minutes after IVIg infusion.	(64)
Primary immune thrombocytopenia	Prospective controlled	IVIg	1 g/kg/day for consecutive 2 days (IV)	·Pre-infusion vs.2 days after infusion ·Pre-infusion vs. week 4 after infusion	↑ CD4⁺CD25⁺Foxp3⁺	IVIg induced expansion of Treg cells at day 2 and week 4 after infusion.	(65)
Healthy human subjects	Prospective uncontrolled	Autologous total IgG	0.4 g (8 injection of 50 mg per 4 weeks) (IM)	Pre-injection (0 week) vs. weeks 4, 8, and 12	↑ IL-10-producing CD4⁺ ↑ IFN-γ-producing CD3⁺	Intramuscular injection of autologous total IgG increased IL-10-producing CD4⁺ T cells at weeks 4, 8, and 12 compared to baseline (0 week).	(46)
Atopic dermatitis	RCT	Autologous total IgG	0.4 g (8 injection of 50 mg per 7 weeks) (IM)	Pre-injection (0 week) vs. week 16	↑ IL-10-producing CD4⁺	Intramuscular injection of autologous total IgG increased Treg cells at week 16 compared to baseline (0 week).	(66)

Open in a new tab

IgG, immunoglobulin G; Treg cell, regulatory T cell; IVIg, purified polyvalent IgG from the plasma pool of multiple healthy human blood donors; Foxp3, forkhead box P3; IV, intravenous; IM, intramuscular; IL, interleukin; IFN, interferon; RCT, randomized clinical trial.

3.2. Clinical application of “active anti-idiotypic therapy” with polyvalent IgG: lessons obtained from clinical trials on intramuscular injection of autologous total IgG in patients with atopic dermatitis

An author (Nahm DH) of this review has tried to develop a new anti-idiotypic therapy through intramuscular injection of autologous total IgG purified from autologous blood via affinity-chromatography using protein A bead in patients with atopic dermatitis (AD) and healthy human subjects (46, 66–70). From clinical trials in patients with AD and healthy human subjects, the novel concept of an “active anti-idiotypic therapy” was developed as described in the following sections.

3.2.1. Current knowledge on pathogenesis and treatment of atopic dermatitis

AD is an allergic skin disorder characterized by chronic allergic inflammation of the skin with clinical manifestations including itching, dry skin, exudation, and frequently associated with a personal or familial history of allergic diseases (2, 71, 72).

In patients with AD, allergic inflammation of the skin is characterized by the uptake of allergens by APCs that digest allergens and present peptides of the allergen to allergen-specific CD4⁺ T cells, which secrete Th2 cytokines (IL-4, IL-5, and IL-13) (73). Upon re-exposure, allergens activate Th2 cells to secrete Th2 cytokines, and allergens also bind to IgE antibodies on the mast cells and induce mast cell degranulation and release of chemical mediators, including histamine and other chemo-attractants. These cytokines and chemical mediators induce chronic allergic inflammation (Th2 inflammation) of the skin and clinical symptoms of AD (itching and eczema) (73).

Current topical and systemic immunosuppressants (corticosteroids, cyclosporine, tacrolimus, and methotrexate) nonspecifically suppress inflammatory immune cells and have limited clinical efficacy in patients with moderate-to-severe AD (2). Recently developed monoclonal antibodies to IL-4 receptor alpha or Janus kinase inhibitors suppressing Th2 cell-mediated inflammation demonstrated clinical improvements in a significant number of patients with moderate-to-severe AD (74–77). However, the clinical efficacies of current medical therapies for AD are transient and remain incomplete (71, 78). Therefore, developing a new therapeutic modality modifying the long-term clinical course of AD is needed.

3.2.2. Critical role of decreased number and/or function of Treg cells in the pathogenesis of atopic dermatitis

While Th2 cells may promote allergic inflammation, Treg cells can downregulate Th2 cell function and suppress allergic inflammations. T cell tolerance mediated by Treg cells is the key mechanism underlying immune tolerance in a healthy immune response to self and non-infectious foreign antigens. Immune dysfunction characterized by decreased Treg cell function (reflected by the decreased number and/or function of Treg cells) (79, 80) and excessive activation of Th2 cells producing IL-4 and IL-13 plays a key role in the pathogenesis of AD (2).

Therefore, immunomodulatory therapies to restore Treg cell number and/or function and Th1/Th2-cell balance might be a reasonable approach to induce a long-term treatment-free clinical remission in patients with AD (2, 81).

3.2.3. Immunomodulatory therapies that induced a long-term treatment-free clinical remission in patients with atopic dermatitis

3.2.3.1. Allergen immunotherapy

Allergen immunotherapy is a treatment that involves the repeated administration of sensitized allergens either subcutaneously or sublingually to induce allergen-specific immune tolerance in patients with allergic diseases (82, 83). Allergen immunotherapy is clinically beneficial in AD patients sensitized to house dust mites in a meta-analysis of multiple randomized clinical trials (84, 85). Clinical observational studies reported long-term treatment-free clinical remissions in patients with AD after allergen immunotherapy (86–88). Allergen immunotherapy activates allergen-specific Treg cells to downregulate Th2 cell- and IgE-mediated allergic inflammation. Treg cells are generated during allergen immunotherapy, secrete IL-10, and induce allergen-specific B cells to produce IgG4 antibodies (89). These mechanisms induce tolerance to antigens that reduce allergic symptoms. Induction of peripheral T cell tolerance by Treg cells is the key mechanism involved in allergen immunotherapy (90). Activated Treg cells release IL-10 and suppress Th2 cell-mediated allergic inflammation. However, there are still controversies regarding the main subpopulation of Treg cells mediating therapeutic effects involved in allergen immunotherapy (CD4⁺Foxp3⁺ Treg cells and/or CD4⁺Foxp3^-IL-10⁺ Treg cells) (91).

3.2.3.2. Natural remission of disease in children with atopic dermatitis

More than 70% of children with AD experience natural remission of their disease before puberty (92); although the mechanism of natural remission of AD in children has not been determined yet, induction of immune tolerance due to activation of Treg cells has been suggested as a mechanism (2). Induction of immune tolerance mimicking the immunological mechanism responsible for the natural clinical remission of AD in children could be an ideal way to achieve clinical remission in patients with AD (2).

3.2.3.3. Intramuscular administration of autologous polyvalent IgG for induction of anti-idiotype immune modulation

An author of this review (Nahm DH) hypothesized that immunizing the human subjects with autologous immunoglobulin might induce Treg cell response with systemic immunomodulatory effects to prevent or treat AD. To evaluate this hypothesis, clinical trials were performed to evaluate the clinical efficacy and immunomodulatory effect of intramuscular administration of autologous polyvalent IgG (total IgG) purified from autologous blood using Protein A bead in patients with AD and healthy human subjects (46, 66–70).

In a randomized controlled trial including 51 patients with AD, 8 weekly intramuscular injections of autologous total IgG (50 mg) for 7 weeks resulted in significant clinical improvements and increased serum levels of IL-10 and interferon (IFN)-γ at week 16 (66). In this study, the percentages of IL-10- and IFN-γ-producing cells in the peripheral blood CD4⁺ T cells were increased after the intramuscular administration of autologous total IgG in patients with AD (66). These results suggested that intramuscular administration of low doses of autologous total IgG can activate Treg cells and Th1 cells producing IFN-γ and lead to systemic immunomodulatory effects in patients with AD (66).

In a previous clinical study, a long-term clinical improvement for more than nine months was observed in 2 of 3 patients with severe AD who received 8 intramuscular injections of autologous total IgG 50 mg (total 400 mg) for 4 weeks and were followed up for two years (69). In this study, two of three patients showed clinical improvement for more than 36 weeks after treatment with maximum decreases in clinical severity score greater than 80% from baseline. These two patients showed a long-term (more than 36 weeks) decrease in serum total IgE concentration and peripheral blood eosinophil count with maximum decreases in those values greater than 70% from baseline. No significant side effect was observed during the two years of follow-up period in all three patients (69). This observation suggests a potential of intramuscular administration of autologous total IgG in modifying the long-term disease course of AD.

Changes in T cells before and after intramuscular administration of autologous total IgG were evaluated in 13 healthy human subjects (46). Intramuscular administration of autologous total IgG (8 injections of autologous IgG 50 mg per 4 weeks; total 400 mg IgG) significantly increased the percentage of IL-10-producing CD4⁺ T cells in peripheral blood CD4⁺ T cells and the percentage of IFN-γ-producing CD3⁺ T cells in peripheral blood CD3⁺ T cells in healthy human subjects (46) ( Table 3 ). These results suggest that intramuscular administration of autologous total IgG can activate Treg cells and IFN-γ-producing T cells in healthy subjects and that it could be a safe and effective method to activate Treg cells in human subjects (46). The significant limitations of these clinical studies are the lack of knowledge on the detailed molecular mechanism underlying Treg cell activation induced by autologous total IgG and the subpopulation of Treg cells (CD4⁺Foxp3⁺ Treg cells and/or CD4⁺Foxp3^-IL-10⁺ Treg cells) activated by autologous total IgG.

An author of this review (Nahm DH) speculates that the intramuscular administration of autologous total IgG activates pre-existing anti-idiotypic Treg cells that can specifically recognize peptides derived from IgG idiotypes by their TCRs and produce IL-10, based on the observations in healthy human subjects after intramuscular injection of autologous total IgG (46). However, a direct experimental demonstration of the existence or development of anti-idiotypic Treg cells has not been provided yet. Therefore, an author (Nahm DH) of this review proposes that “anti-idiotypic Treg cell” is a missing scientific link that can integrate both “idiotypic network theory” and “Treg cell theory” to explain the mechanism underlying the maintenance of an immune tolerance state ( Tables 1 , 4 ).

Table 4.

Ten future research topics on the detailed mechanism underlying polyvalent IgG-induced activation of regulatory T cells and its clinical application.

Questions for future research topics

1) Which subpopulation of Treg cells responsible for the immunomodulatory effect of polyvalent IgG? (Tr1 cells or Foxp3⁺ Treg cells)?
2) Can the peptides from idiotypes of the IgG processed by antigen-presenting cells induce a differentiation of naive CD4⁺ T cells into Treg cells or an activation of pre-existing resting anti-idiotypic Treg cells?
3) Can the direct binding of polyvalent IgG to T cell receptors on the surface of Treg or antigens in the antigen-presenting cells induce activation of Treg cells?
4) Can intramuscular or subcutaneous injection of autologous polyvalent IgG induce activation of Treg cells specific to peptides derived from idiotypes of autologous IgG (anti-idiotypic Treg cells)?
5) Can the existence of anti-idiotypic Treg cell be demonstrated by experiments in cell culture condition or animal models?
6) Can intramuscular or subcutaneous injection of autologous polyvalent IgG increase the production of anti-idiotypic antibodies?
7) Is there any difference in the immunomodulatory effects and clinical efficacy between intravenous injection of polyvalent IgG from healthy blood donors and intramuscular or subcutaneous injection of autologous polyvalent IgG in patients with allergic or autoimmune diseases?
8) Is there a difference in immunomodulatory mechanism induced by intravenous injection of polyvalent IgG from healthy blood donors or intramuscular or subcutaneous injection of autologous polyvalent IgG?
9) Can intramuscular or subcutaneous injection of autologous polyvalent IgG induce long-term clinical improvements in patients with allergic and autoimmune diseases more efficiently compared with intravenous injection of polyvalent IgG from healthy blood donors?
10) Are the concepts of passive anti-idiotype therapy for the explanation of the therapeutic mechanism of intravenous injection of polyvalent IgG from healthy blood donors (supplementing natural anti-idiotypic antibodies to neutralize pathogenic antibodies) and active anti-idiotypic therapy for the induction of anti-idiotypic Treg cell and B cell responses by intramuscular or subcutaneous injection of autologous polyvalent IgG correct?

Open in a new tab

IgG, immunoglobulin G; Treg cell, regulatory T cell; Tr1 cell, type 1 regulatory T cell; nTreg cell, natural regulatory T cell; Foxp3, forkhead box P3.

3.2.3.4. Comparison of efficacy and mechanism of intravenous injection of heterologous polyvalent IgG and intramuscular injection of autologous total IgG in patients with atopic dermatitis

Expansion of CD4⁺ Foxp3⁺ Treg cells in the peripheral blood has been reported in patients with autoimmune diseases after intravenous administration of high-dose (1~2 g/Kg of body weight) heterologous IVIg (60, 65, 93). Continuous regular intravenous infusion of a high dose of polyvalent human IgG is needed to achieve a long-term clinical improvement in patients with autoimmune diseases (60, 91, 93). This requirement of continuous treatment has been attributed to the low concentration and low affinity of natural anti-idiotype antibodies to pathogenic autoantibodies contained in IVIg (17). Clinical trials on high-dose intravenous polyvalent IgG therapy (1~2 g/Kg of body weight per patient) in adult patients with severe AD showed no significant clinical benefit (93). However, intramuscularly administered low doses of purified autologous total IgG (8 intramuscular injections of autologous total IgG 50 mg for 4 weeks) produced potent immunomodulatory effects (increased serum levels of IL-10 and IFN- γ) and long-term clinical improvement compared to intravenous administration of a high dose of heterologous IgG (1~2 g/Kg of body weight per a patient) in adolescent and adult patients with AD (66, 93). These conflicting results from clinical trials on the intravenous administration of heterologous IgG and intramuscular administration of autologous IgG in patients with AD suggest that differences in the origin of polyvalent IgG (heterologous vs. autologous) and route of administration of polyvalent IgG (intravenous vs. intramuscular) can result in different immunomodulatory effects and clinical efficacy (66).

If polyvalent IgG is used as an “antibody” to neutralize pathogenic antibodies (IgG autoantibodies or IgE antibodies), intravenous administration of polyvalent IgG can be the preferred route of administration (66). However, if polyvalent IgG is used as an “antigen” to activate anti-idiotypic Treg cells in patients with allergic and autoimmune diseases, the intramuscular or subcutaneous administration route might be an ideal route of administration. A specific antigen administered through intravenous injection preferentially interacts with mononuclear cells in the peripheral blood, and a specific antigen administered through intramuscular or subcutaneous injection preferentially interacts with DCs (66).

Intramuscularly administered autologous polyvalent IgG may more efficiently activate pre-existing idiotype-specific Treg cells than with intramuscularly administered heterologous IgG because the pre-existence of idiotype-specific T cell to autologous IgG is an essential prerequisite of the “idiotype-network theory.” The potency of activation of Treg cells induced through intramuscular injection of heterologous polyvalent IgG can be weak because of a smaller number of pre-existing idiotype-specific Treg cells than that in case of intramuscular injection of autologous polyvalent IgG.

Further studies are necessary to evaluate the detailed mechanisms underlying systemic immunomodulation induced by intravenous or intramuscular administration of heterologous or autologous human IgG, especially on the mechanism of anti-idiotypic immunomodulation.

3.3. In vitro and animal studies about IgG-mediated anti-idiotypic immuno-modulation: lessons from experiments using IgG from donors with various immune backgrounds

3.3.1. Immunomodulatory effects induced by polyvalent IgG from donors with various immune backgrounds

In a mouse model of OVA-allergy, the passive transference of polyclonal IgG from allergen-immunized donors to non-immunized pregnant mice increased IL-10-producing CD4⁺ T cells in the offspring at birth and prevented neonatal OVA-sensitization (47). This effect occurs in the absence of maternal antigen immunization, suggesting that the in vivo effect was mediated by idiotypic interactions between the polyvalent IgG from allergen-immunized donors administered to the mother during pregnancy and the fetus lymphocytes (47).

A study suggested that IgG also permeates cells and interacts with intracellular molecules, inhibiting T cell activation after its interaction with nuclear and cytoplasmic components (94). These cell-penetrating antibodies, which could be detected in polyvalent IgG formulations, penetrate various mammalian cell lines and represent ~2% of polyvalent IgG. This possibility also needs to be discussed because it suggests that anti-idiotype IgG may interact with TCRs intracellularly, at an early stage of production of these receptors.

3.3.2. Experimental observations regarding IgG from patients with atopic dermatitis

It has been demonstrated that AD patients can produce detectable levels of anti-IgE autoantibodies in the IgG class (95) and that these antibodies can mediate inflammatory mediators released from basophils and mast cells (96). This observation was confirmed by two studies which showed that the functional activity of IgG anti-IgE autoantibodies from patients with AD induced the release of pro-inflammatory mediators and cytokines from human basophils and mast cells (97, 98).

Human thymic lymphocyte culture with purified IgG showed that pooled IgG from patients with AD could more effectively modulate cytokine production from thymic CD4⁺ T cells than did polyvalent IgG from healthy human subjects (IVIg) (99). This study demonstrates that IgG from patients with AD induced significantly higher production of IL-17 and IL-10 by intrathymic immature double positive and mature CD4⁺ T cells than did polyvalent IgG from healthy individuals (99). In a similar in vitro experiment, pooled IgG from patients with AD could induce thymic invariant natural killer T cells (CD1d-restricted T cells that employ an invariant TCR alpha chain and a limited repertoire of beta chains) to produce higher levels of intracellular IL-4, IL-10, and IL-17 than did polyvalent IgG from healthy non-atopic individuals (100). The IgG-reactivity toward 1152 human protein fragments was evaluated in 80 individuals (AD patients and healthy controls), and a significant differential IgG-reactivity to four antigens representing keratin-associated protein 17-1 (KRTAP17-1), heat shock protein family A member 4 (HSPA4), S100 calcium-binding proteins A12, and Z (S100A12 and S100Z) was detected (101). The reactivity to these four antigens was more frequent in the patients with severe AD (66%) than in patients with moderate AD (41%) and healthy controls (25%) (101). These observations suggest that purified IgG from patients with AD can modulate T cells more efficiently than does polyvalent IgG from healthy human subjects (IVIg) (99, 100, 102).

4. Six questions on the mechanism underlying polyvalent IgG-induced activation of Treg cells and its clinical application for the treatment of immune diseases

We asked six critical questions regarding the mechanism and its clinical application of polyvalent IgG-induced immune modulation and activation of Treg cells ( Table 1 ). We propose one hypothesis to provide an answer to these six questions regarding the mechanism of polyvalent IgG induced activation of Treg cells and its clinical application ( Box 1 ). These six questions and one hypothesis should be validated in future studies.

Box 1. A new concept of active anti-idiotypic therapy with autologous polyvalent IgG for allergic and autoimmune diseases.

“Subcutaneous or intramuscular administration of autologous polyvalent IgG can activate anti-idiotypic regulatory T cells that can specifically recognize immunogenic peptides generated from idiotypes of autologous IgG by dendritic cells. The activated anti-idiotypic regulatory T cells can induce an immune tolerance state (recovery of immune homeostasis) and a long-term treatment-free clinical remission in patients with allergic and autoimmune diseases.”

IgG, immunoglobulin G.

In this hypothesis, subcutaneous or intramuscular injection of autologous polyvalent IgG can induce activation of anti-idiotypic Treg cells to downregulate the production of pathogenic antibodies and exaggerated T cell responses harmful to the host and induce an immune tolerance state and ultimately induce a long-term clinical remission in patients with autoimmune and allergic diseases ( Box 1 ). Through the perspective of the idiotypic network theory, immunization with autologous polyvalent IgG might provide a more potent immunomodulatory effects than that provided by heterologous polyvalent IgG in the treatment of autoimmune and allergic diseases.

5. Future research directions (research topics) involving the mechanism and clinical application of polyvalent IgG-induced activation of Treg cells

Polyvalent IgG can induce activation of Treg cells to produce IL-10 and exert a systemic immunomodulatory effect and clinical efficacy in patients with allergic and autoimmune diseases. However, this review also exposed a lack of current knowledge regarding the mechanism of polyvalent IgG-induced immunomodulation including Treg cell activation and its role in the development and maintenance of immune tolerance. Therefore, we provide our hypotheses (unproved speculations on the detailed mechanism) to promote further research on this important but neglected research topic by other colleagues. For future investigations, we propose research topics to answer questions on the detailed mechanism and clinical application of polyvalent IgG-induced immunomodulation ( Table 4 ).

6. Conclusion

Experimental studies and clinical trials involving Treg cells suggest that polyvalent IgG acts as a stimulator of Treg cells. However, the mechanism underlying the activation of Treg cells by polyvalent IgG is not defined yet. We hypothesize that anti-idiotypic Treg cells can be activated via intramuscular or subcutaneous injection of autologous polyvalent IgG because idiotypes of polyvalent IgG can act as antigens. The activated anti-idiotypic Treg cells secrete IL-10, and IL-10 suppresses Th2 cell responses to allergens and autoimmune T cell responses to self-antigens and thus can induce a long-term clinical remission of allergic and autoimmune diseases. Further studies are needed to evaluate the detailed molecular mechanism underlying polyvalent IgG-induced Treg cell activation and the clinical usefulness of this immunomodulatory strategy for the treatment of allergic and autoimmune diseases.

Author contributions

All authors contributed in writing and revising the manuscript. DN: Conceptualization, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing. JV: Funding acquisition, Writing – original draft, Writing – review & editing. All authors contributed to the article and approved the submitted version.

Acknowledgments

This collaborative work was started by DN’s initial email contact and suggestion to JV.

Funding Statement

The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1D1A1B07045762), by the Laboratory of Medical Investigation-56, Medical School, University of São Paulo, São Paulo, Brazil (LIM-56 HC-FMUSP), by the National Council for Scientific and Technological Development (CNPq) grant# 302937/2021-8, and by the São Paulo Research Foundation (FAPESP) grant #2021/08225-8.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell (2008) 133(5):775–87. doi: 10.1016/j.cell.2008.05.009 [DOI] [PubMed] [Google Scholar]
2. Nahm DH. Personalized immunomodulatory therapy for atopic dermatitis: an allergist's view. Ann Dermatol (2015) 27(4):355–63. doi: 10.5021/ad.2015.27.4.355 [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol (2013) 4:152. doi: 10.3389/fimmu.2013.00152 [DOI] [PMC free article] [PubMed] [Google Scholar]
4. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol (2020) 38:541–66. doi: 10.1146/annurev-immunol-042718-041717 [DOI] [PubMed] [Google Scholar]
5. Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat Rev Drug Discovery (2019) 18(10):749–69. doi: 10.1038/s41573-019-0041-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
6. Fontenot JD, Gavin MA, Rudensky AY. FOXP3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol (2003) 4(4):330–6. doi: 10.1038/ni904 [DOI] [PubMed] [Google Scholar]
7. Riemann M, Andreas N, Fedoseeva M, Meier E, Weih D, Freytag H, et al. Central immune tolerance depends on crosstalk between the classical and alternative NF-κB pathways in medullary thymic epithelial cells. J Autoimmun (2017) 81:56–67. doi: 10.1016/j.jaut.2017.03.007 [DOI] [PubMed] [Google Scholar]
8. Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harbor Perspect Biol (2012) 4(6):a006957. doi: 10.1101/cshperspect.a006957 [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest (1996) 98(7):1676–83. doi: 10.1172/JCI118963 [DOI] [PMC free article] [PubMed] [Google Scholar]
10. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 102(1):98–106. doi: 10.1172/JCI2250 [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 111(6):1255–61. doi: 10.1067/mai.2003.1570 [DOI] [PubMed] [Google Scholar]
12. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol (2003) 33(5):1205–14. doi: 10.1002/eji.200322919 [DOI] [PubMed] [Google Scholar]
13. Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev (2014) 259(1):88–102. doi: 10.1111/imr.12160 [DOI] [PMC free article] [PubMed] [Google Scholar]
14. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol (2005) 142(1):1–11. doi: 10.1111/j.1365-2249.2005.02834.x [DOI] [PMC free article] [PubMed] [Google Scholar]
15. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med (1991) 325(2):110–7. doi: 10.1056/NEJM199107113250207 [DOI] [PubMed] [Google Scholar]
16. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 345(10):747–55. doi: 10.1056/NEJMra993360 [DOI] [PubMed] [Google Scholar]
17. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med (2012) 367(21):2015–25. doi: 10.1056/NEJMra1009433 [DOI] [PubMed] [Google Scholar]
18. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol (2017) 29(11):491–8. doi: 10.1093/intimm/dxx039 [DOI] [PubMed] [Google Scholar]
19. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol (2007) 179(8):5571–5. doi: 10.4049/jimmunol.179.8.5571 [DOI] [PubMed] [Google Scholar]
20. Maddur MS, Kaveri SV, Bayry J. Circulating normal IgG as stimulator of regulatory T cells: lessons from intravenous immunoglobulin. Trends Immunol (2017) 38(11):789–92. doi: 10.1016/j.it.2017.08.008 [DOI] [PubMed] [Google Scholar]
21. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4+ CD25+ Regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood (2008) 111(2):715–22. doi: 10.1182/blood-2007-03-079947 [DOI] [PubMed] [Google Scholar]
22. Lories RJ, Casteels-Van Daele M, Ceuppens JL, Van Gool SW. Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro. Ann Rheum Dis (2004) 63(6):747–8. doi: 10.1136/ard.2003.007138 [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the FC portion and independent of sialylation or basophils. J Immunol (2014) 192(11):5031–8. doi: 10.4049/jimmunol.1301611 [DOI] [PMC free article] [PubMed] [Google Scholar]
24. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory FC receptor. Science (2001) 291(5503):484–6. doi: 10.1126/science.291.5503.484 [DOI] [PubMed] [Google Scholar]
25. Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN. Dissecting the molecular mechanism of IVIG therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or FC domain. J Mol Biol (2013) 425(8):1253–8. doi: 10.1016/j.jmb.2013.02.006 [DOI] [PubMed] [Google Scholar]
26. Jain A, Olsen HS, Vyzasatya R, Burch E, Sakoda Y, Mérigeon EY, et al. Fully recombinant IgG2a Fc multimers (Stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. Arthritis Res Ther (2012) 14(4):R192. doi: 10.1186/ar4024 [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Thiruppathi M, Sheng JR, Li L, Prabhakar BS, Meriggioli MN. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun (2014) 52:64–73. doi: 10.1016/j.jaut.2013.12.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
28. Zhang X, Owens J, Olsen HS, So E, Burch E, McCroskey MC, et al. A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity. JCI Insight (2019) 4(2):e121905. doi: 10.1172/jci.insight.121905 [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Niknami M, Wang MX, Nguyen T, Pollard JD. Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (Experimental autoimmune neuritis). J Peripher Nerv Syst (2013) 18(2):141–52. doi: 10.1111/jns5.12022 [DOI] [PubMed] [Google Scholar]
30. Debré M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 342(8877):945–9. doi: 10.1016/0140-6736(93)92000-j [DOI] [PubMed] [Google Scholar]
31. Käsermann F, Boerema DJ, Rüegsegger M, Hofmann A, Wymann S, Zuercher AW, et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PloS One (2012) 7(6):e37243. doi: 10.1371/journal.pone.0037243 [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Ballow M. Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol (2014) 14(6):509–15. doi: 10.1097/ACI.0000000000000116 [DOI] [PubMed] [Google Scholar]
33. Seite J-F, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 7(6):435–9. doi: 10.1016/j.autrev.2008.04.012 [DOI] [PubMed] [Google Scholar]
34. Fuchs S, Feferman T, Meidler R, Brenner T, Laub O, Souroujon MC. The disease-specific arm of the therapeutic effect of intravenous immunoglobulin in autoimmune diseases: experimental autoimmune myasthenia gravis as a model. Isr Med Assoc J (2008) 10(1):58–60. [PubMed] [Google Scholar]
35. Wallmann J, Pali-Scholl I, Jensen-Jarolim E. Anti-ids in allergy: timeliness of a classic concept. World Allergy Organ J (2010) 3(6):195–201. doi: 10.1097/WOX.0b013e3181e61ebf [DOI] [PMC free article] [PubMed] [Google Scholar]
36. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med (2004) 10(1):17–8. doi: 10.1038/nm0104-17 [DOI] [PubMed] [Google Scholar]
37. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) (1974) 125C(1-2):373–89. [PubMed] [Google Scholar]
38. Lopez-Requena A, Mateo De Acosta C, Vazquez AM, Perez R. Immunogenicity of autologous immunoglobulins: principles and practices. Mol Immunol (2007) 44(11):3076–82. doi: 10.1016/j.molimm.2007.01.005 [DOI] [PubMed] [Google Scholar]
39. Schulz R, Werner B, Behn U. Self-tolerance in a minimal model of the idiotypic network. Front Immunol (2014) 5:86. doi: 10.3389/fimmu.2014.00086 [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2002) 20:621–67. doi: 10.1146/annurev.immunol.20.100301.064828 [DOI] [PubMed] [Google Scholar]
41. Kedzierska AE, Lorek D, Slawek A, Chelmonska-Soyta A. Tregitopes regulate the tolerogenic immune response and decrease the foetal death rate in abortion-prone mouse matings. Sci Rep (2020) 10(1):10531. doi: 10.1038/s41598-020-66957-z [DOI] [PMC free article] [PubMed] [Google Scholar]
42. Massoud AH, Kaufman GN, Xue D, Beland M, Dembele M, Piccirillo CA, et al. Peripherally generated FOXP3(+) regulatory T cells mediate the immunomodulatory effects of IVIg in allergic airways disease. J Immunol (2017) 198(7):2760–71. doi: 10.4049/jimmunol.1502361 [DOI] [PubMed] [Google Scholar]
43. Dembele M, Tao S, Massoud AH, Miah SMS, Lelias S, De Groot AS, et al. Tregitopes improve asthma by promoting highly suppressive and antigen-specific Tregs. Front Immunol (2021) 12:634509. doi: 10.3389/fimmu.2021.634509 [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Sorde L, Spindeldreher S, Palmer E, Karle A. Massive immune response against IVIg interferes with response against other antigens in mice: a new mode of action? PloS One (2017) 12(10):e0186046. doi: 10.1371/journal.pone.0186046 [DOI] [PMC free article] [PubMed] [Google Scholar]
45. Sordé L, Spindeldreher S, Palmer E, Karle A. Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg? Immun Inflammation Dis (2017) 5(4):400–15. doi: 10.1002/iid3.167 [DOI] [PMC free article] [PubMed] [Google Scholar]
46. Kwon B, Yang SJ, Cho SM, Kim ME, Nahm DH. Intramuscular administration of autologous total immunoglobulin G induces immunomodulatory effects on T cells in healthy human subjects: An open-labeled prospective single-arm trial. Med (Baltimore) (2022) 101(22):e29486. doi: 10.1097/MD.0000000000029486 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Victor JR, Muniz BP, Fusaro AE, de Brito CA, Taniguchi EF, Duarte AJ, et al. Maternal immunization with ovalbumin prevents neonatal allergy development and up-regulates inhibitory receptor Fc gamma RIIB expression on B cells. BMC Immunol (2010) 11:11. doi: 10.1186/1471-2172-11-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Lee SY, Jung YO, Ryu JG, Kang CM, Kim EK, Son HJ, et al. Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner. Arthritis Rheumatol (2014) 66(7):1768–78. doi: 10.1002/art.38627 [DOI] [PubMed] [Google Scholar]
49. Ramakrishna C, Newo AN, Shen YW, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PloS Pathog (2011) 7(6):e1002071. doi: 10.1371/journal.ppat.1002071 [DOI] [PMC free article] [PubMed] [Google Scholar]
50. Massoud AH, Guay J, Shalaby KH, Bjur E, Ablona A, Chan D, et al. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3–positive regulatory T cells. J Allergy Clin Immunol (2012) 129(6):1656–65. e3. doi: 10.1016/j.jaci.2012.02.050 [DOI] [PubMed] [Google Scholar]
51. Othy S, Hegde P, Topçu S, Sharma M, Maddur MS, Lacroix-Desmazes S, et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1–mammalian target of rapamycin axis. J Immunol (2013) 190(9):4535–41. doi: 10.4049/jimmunol.1201965 [DOI] [PubMed] [Google Scholar]
52. Victor JR. Do different IgG repertoires play a role in B-and T-cell functional modulation during ontogeny? The “hooks without bait” theory. Immunol Cell Biol (2020) 98(7):540–8. doi: 10.1111/imcb.12335 [DOI] [PubMed] [Google Scholar]
53. de Sousa TR, Fagundes BO, Nascimento A, Fernandes LA, Sgnotto FDR, Orfali RL, et al. IgG from adult atopic dermatitis (AD) patients induces thymic IL-22 production and CLA expression on CD4+ T cells: Possible epigenetic implications mediated by miRNA. Int J Mol Sci (2022) 23(12):6867. doi: 10.3390/ijms23126867 [DOI] [PMC free article] [PubMed] [Google Scholar]
54. Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood (2013) 122(8):1419–27. doi: 10.1182/blood-2012-11-468264 [DOI] [PubMed] [Google Scholar]
55. Massoud AH, Yona M, Xue D, Chouiali F, Alturaihi H, Ablona A, et al. Dendritic cell immunoreceptor: A novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol (2014) 133(3):853–63.e5. doi: 10.1016/j.jaci.2013.09.029 [DOI] [PubMed] [Google Scholar]
56. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 27(3):233–45. doi: 10.1007/s10875-007-9088-9 [DOI] [PubMed] [Google Scholar]
57. Abbott JK, Chan SK, MacBeth M, Crooks JL, Hancock C, Knight V, et al. Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles. PloS One (2022) 17(3):e0265852. doi: 10.1371/journal.pone.0265852 [DOI] [PMC free article] [PubMed] [Google Scholar]
58. Bayry J, Mouthon L, Kaveri SV. Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J Rheumatol (2012) 39(2):450–1. doi: 10.3899/jrheum.111123 [DOI] [PMC free article] [PubMed] [Google Scholar]
59. Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-barré syndrome patients. Immunol Res (2014) 60(2-3):320–9. doi: 10.1007/s12026-014-8580-6 [DOI] [PubMed] [Google Scholar]
60. Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol (2012) 39(5):1019–25. doi: 10.3899/jrheum.110981 [DOI] [PubMed] [Google Scholar]
61. Olivito B, Taddio A, Simonini G, Massai C, Ciullini S, Gambineri E, et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol (2010) 28(1 Suppl 57):93–7. [PubMed] [Google Scholar]
62. Jafarzadeh S, Ahmadi M, Dolati S, Aghebati-Maleki L, Eghbal-Fard S, Kamrani A, et al. Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function. J Cell Biochem (2019) 120(4):5424–34. doi: 10.1002/jcb.27821 [DOI] [PubMed] [Google Scholar]
63. Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, Aghebati-Maleki L, Dolati S, Farzadi L, et al. Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment. Syst Biol Reprod Med (2017) 63(6):350–9. doi: 10.1080/19396368.2017.1390007 [DOI] [PubMed] [Google Scholar]
64. Kasztalska K, Ciebiada M, Cebula-Obrzut B, Gorski P. Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study. Clin Drug Investig (2011) 31(5):299–307. doi: 10.1007/BF03256928 [DOI] [PubMed] [Google Scholar]
65. Wang SC, Yang KD, Lin CY, Huang AY, Hsiao CC, Lin MT, et al. Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia. Pediatr Blood Cancer (2020) 67(2):e28075. doi: 10.1002/pbc.28075 [DOI] [PubMed] [Google Scholar]
66. Nahm DH, Ye YM, Shin YS, Park HS, Kim ME, Kwon B, et al. Efficacy, safety, and immunomodulatory effect of the intramuscular administration of autologous total immunoglobulin G for atopic dermatitis: A randomized clinical trial. Allergy Asthma Immunol Res (2020) 12(6):949–63. doi: 10.4168/aair.2020.12.6.949 [DOI] [PMC free article] [PubMed] [Google Scholar]
67. Nahm DH, Cho SM, Kim ME, Kim YJ, Jeon SY. Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: A preliminary report. Allergy Asthma Immunol Res (2014) 6(1):89–94. doi: 10.4168/aair.2014.6.1.89 [DOI] [PMC free article] [PubMed] [Google Scholar]
68. Nahm DH, Kim ME, Cho SM. Effects of intramuscular injection of autologous immunoglobulin on clinical severity and serum IgE concentration in patients with atopic dermatitis. Dermatology (2015) 231(2):145–51. doi: 10.1159/000431173 [DOI] [PubMed] [Google Scholar]
69. Nahm DH, Ahn A, Kim ME, Cho SM, Park MJ. Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: long-term changes of clinical severity and laboratory parameters. Allergy Asthma Immunol Res (2016) 8(4):375–82. doi: 10.4168/aair.2016.8.4.375 [DOI] [PMC free article] [PubMed] [Google Scholar]
70. Cho SM, Kim ME, Kwon B, Nahm DH. Immunomodulatory effects induced by intramuscular administration of autologous total immunoglobulin G in patients with atopic dermatitis. Int Immunopharmacol (2017) 52:1–6. doi: 10.1016/j.intimp.2017.08.020 [DOI] [PubMed] [Google Scholar]
71. Weidinger S, Novak N. Atopic dermatitis. Lancet (2016) 387(10023):1109–22. doi: 10.1016/S0140-6736(15)00149-X [DOI] [PubMed] [Google Scholar]
72. Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther (2013) 13(4):549–61. doi: 10.1517/14712598.2013.758708 [DOI] [PMC free article] [PubMed] [Google Scholar]
73. Broide DH. Immunomodulation of allergic disease. Annu Rev Med (2009) 60:279–91. doi: 10.1146/annurev.med.60.041807.123524 [DOI] [PMC free article] [PubMed] [Google Scholar]
74. Wang FP, Tang XJ, Wei CQ, Xu LR, Mao H, Luo FM. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci (2018) 90(2):190–8. doi: 10.1016/j.jdermsci.2018.01.016 [DOI] [PubMed] [Google Scholar]
75. Agache I, Song Y, Posso M, Alonso-Coello P, Rocha C, Sola I, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy (2021) 76(1):45–58. doi: 10.1111/all.14510 [DOI] [PubMed] [Google Scholar]
76. Sedeh FB, Henning MAS, Jemec GBE, Ibler KS. Comparative efficacy and safety of monoclonal antibodies and Janus Kinase Inhibitors in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Acta Derm Venereol (2022) 102:adv00764. doi: 10.2340/actadv.v102.2075 [DOI] [PMC free article] [PubMed] [Google Scholar]
77. Werfel T. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018. Curr Opin Allergy Clin Immunol (2018) 18(5):432–7. doi: 10.1097/ACI.0000000000000477 [DOI] [PubMed] [Google Scholar]
78. Nankervis H, Thomas K, Delamere FM, Barbarot S, Smith S, Rogers NK, et al. What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials. Br J Dermatol (2017) 176(4):910–27. doi: 10.1111/bjd.14999 [DOI] [PubMed] [Google Scholar]
79. Agrawal R, Wisniewski JA, Woodfolk JA. The role of regulatory T cells in atopic dermatitis. Curr Probl Dermatol (2011) 41:112–24. doi: 10.1159/000323305 [DOI] [PMC free article] [PubMed] [Google Scholar]
80. Samochocki Z, Alifier M, Bodera P, Jeziorkowska R, Rosiak E, Jurkiewicz B, et al. T-regulatory cells in severe atopic dermatitis: alterations related to cytokines and other lymphocyte subpopulations. Arch Dermatol Res (2012) 304(10):795–801. doi: 10.1007/s00403-012-1290-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
81. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy (2013) 68(8):974–82. doi: 10.1111/all.12184 [DOI] [PubMed] [Google Scholar]
82. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A who position paper. J Allergy Clin Immunol (1998) 102(4 Pt 1):558–62. doi: 10.1016/s0091-6749(98)70271-4 [DOI] [PubMed] [Google Scholar]
83. Berings M, Karaaslan C, Altunbulakli C, Gevaert P, Akdis M, Bachert C, et al. Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol (2017) 140(5):1250–67. doi: 10.1016/j.jaci.2017.08.025 [DOI] [PubMed] [Google Scholar]
84. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol (2013) 132(1):110–7. doi: 10.1016/j.jaci.2013.02.044 [DOI] [PubMed] [Google Scholar]
85. Yepes-Nunez JJ, Guyatt GH, Gomez-Escobar LG, Perez-Herrera LC, Chu AWL, Ceccaci R, et al. Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol (2023) 151(1):147–58. doi: 10.1016/j.jaci.2022.09.020 [DOI] [PubMed] [Google Scholar]
86. Chait I, Allkins V. Remission of life-long atopic dermatitis after hyposensitisation to house dust mite. Practitioner (1985) 229(1405):609–12. [PubMed] [Google Scholar]
87. Leroy BP, Lachapelle J-M, Somville M, Jacquemin M, Saint-Remy J. Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis. Dermatology (1991) 182(2):98–106. doi: 10.1159/000247754 [DOI] [PubMed] [Google Scholar]
88. Tuft L. Studies in atopic dermatitis: V. Problems in inhalant hyposensitization and results of treatment. J Allergy (1960) 31(1):1–11. doi: 10.1016/0021-8707(60)90019-8 [DOI] [PubMed] [Google Scholar]
89. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol (2016) 137(2):358–68. doi: 10.1016/j.jaci.2015.12.1300 [DOI] [PubMed] [Google Scholar]
90. Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy–T-cell tolerance and more. Allergy (2006) 61(7):796–807. doi: 10.1111/j.1398-9995.2006.01175.x [DOI] [PubMed] [Google Scholar]
91. Matsuda M, Terada T, Kitatani K, Kawata R, Nabe T. Roles of type 1 regulatory T (Tr1) cells in allergen-specific immunotherapy. Front Allergy (2022) 3:981126. doi: 10.3389/falgy.2022.981126 [DOI] [PMC free article] [PubMed] [Google Scholar]
92. Hua TC, Hwang CY, Chen YJ, Chu SY, Chen CC, Lee DD, et al. The natural course of early-onset atopic dermatitis in Taiwan: A population-based cohort study. Br J Dermatol (2014) 170(1):130–5. doi: 10.1111/bjd.12603 [DOI] [PubMed] [Google Scholar]
93. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol (2017) 139(3S):S1–S46. doi: 10.1016/j.jaci.2016.09.023 [DOI] [PubMed] [Google Scholar]
94. Sali AD, Karakasiliotis I, Evangelidou M, Avrameas S, Lymberi P. Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin. Clin Transl Immunol (2015) 4(10):e42. doi: 10.1038/cti.2015.18 [DOI] [PMC free article] [PubMed] [Google Scholar]
95. Nawata Y, Koike T, Hosokawa H, Tomioka H, Yoshida S. Anti-IgE autoantibody in patients with atopic dermatitis. J Immunol (1985) 135(1):478–82. doi: 10.4049/jimmunol.135.1.478 [DOI] [PubMed] [Google Scholar]
96. Marone G, Casolaro V, Paganelli R, Quinti I. IgG anti-IgE from atopic dermatitis induces mediator release from basophils and mast cells. J Invest Dermatol (1989) 93(2):246–52. doi: 10.1111/1523-1747.ep12277582 [DOI] [PubMed] [Google Scholar]
97. Poto R, Patella V, Criscuolo G, Marone G, Coscioni E, Varricchi G. Autoantibodies to IgE can induce the release of proinflammatory and vasoactive mediators from human cardiac mast cells. Clin Exp Med (2022) 23(4):1265–76. doi: 10.1007/s10238-022-00861-w [DOI] [PMC free article] [PubMed] [Google Scholar]
98. Poto R, Quinti I, Marone G, Taglialatela M, de Paulis A, Casolaro V, et al. IgG autoantibodies against IgE from atopic dermatitis can induce the release of cytokines and proinflammatory mediators from basophils and mast cells. Front Immunol (2022) 13:880412. doi: 10.3389/fimmu.2022.880412 [DOI] [PMC free article] [PubMed] [Google Scholar]
99. Sgnotto FDR, de Oliveira MG, Lira AAL, Inoue AHS, Titz TO, Orfali RL, et al. IgG from atopic dermatitis patients induces IL-17 and IL-10 production in infant intrathymic TCD4 and TCD8 cells. Int J Dermatol (2018) 57(4):434–40. doi: 10.1111/ijd.13907 [DOI] [PubMed] [Google Scholar]
100. Santos LS, Sgnotto FDR, Sousa TR, Orfali RL, Aoki V, Duarte AJDS, et al. IgG from atopic dermatitis patients induces non-atopic infant thymic invariant natural killer T (iNKT) cells to produce IL-4, IL-17, and IL-10. Int J Dermatol (2019) 59(3):359–64. doi: 10.1111/ijd.14688 [DOI] [PubMed] [Google Scholar]
101. Mikus M, Johansson C, Acevedo N, Nilsson P, Scheynius A. The antimicrobial protein S100A12 identified as a potential autoantigen in a subgroup of atopic dermatitis patients. Clin Transl Allergy (2019) 9:6. doi: 10.1186/s13601-019-0240-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
102. Fagundes BO, de Sousa TR, Nascimento A, Fernandes LA, Sgnotto FDR, Orfali RL, et al. IgG from adult atopic dermatitis (AD) patients induces nonatopic neonatal thymic gamma-delta T cells (ΓδT) to acquire IL-22/IL-17 secretion profile with skin-homing properties and epigenetic implications mediated by miRNA. Int J Mol Sci (2022) 23(12):6872. doi: 10.3390/ijms23126872 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B1] 1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell (2008) 133(5):775–87. doi: 10.1016/j.cell.2008.05.009 [DOI] [PubMed] [Google Scholar]

[B2] 2. Nahm DH. Personalized immunomodulatory therapy for atopic dermatitis: an allergist's view. Ann Dermatol (2015) 27(4):355–63. doi: 10.5021/ad.2015.27.4.355 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B3] 3. Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol (2013) 4:152. doi: 10.3389/fimmu.2013.00152 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B4] 4. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol (2020) 38:541–66. doi: 10.1146/annurev-immunol-042718-041717 [DOI] [PubMed] [Google Scholar]

[B5] 5. Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat Rev Drug Discovery (2019) 18(10):749–69. doi: 10.1038/s41573-019-0041-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B6] 6. Fontenot JD, Gavin MA, Rudensky AY. FOXP3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol (2003) 4(4):330–6. doi: 10.1038/ni904 [DOI] [PubMed] [Google Scholar]

[B7] 7. Riemann M, Andreas N, Fedoseeva M, Meier E, Weih D, Freytag H, et al. Central immune tolerance depends on crosstalk between the classical and alternative NF-κB pathways in medullary thymic epithelial cells. J Autoimmun (2017) 81:56–67. doi: 10.1016/j.jaut.2017.03.007 [DOI] [PubMed] [Google Scholar]

[B8] 8. Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harbor Perspect Biol (2012) 4(6):a006957. doi: 10.1101/cshperspect.a006957 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B9] 9. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest (1996) 98(7):1676–83. doi: 10.1172/JCI118963 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B10] 10. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 102(1):98–106. doi: 10.1172/JCI2250 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B11] 11. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 111(6):1255–61. doi: 10.1067/mai.2003.1570 [DOI] [PubMed] [Google Scholar]

[B12] 12. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol (2003) 33(5):1205–14. doi: 10.1002/eji.200322919 [DOI] [PubMed] [Google Scholar]

[B13] 13. Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev (2014) 259(1):88–102. doi: 10.1111/imr.12160 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B14] 14. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol (2005) 142(1):1–11. doi: 10.1111/j.1365-2249.2005.02834.x [DOI] [PMC free article] [PubMed] [Google Scholar]

[B15] 15. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med (1991) 325(2):110–7. doi: 10.1056/NEJM199107113250207 [DOI] [PubMed] [Google Scholar]

[B16] 16. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 345(10):747–55. doi: 10.1056/NEJMra993360 [DOI] [PubMed] [Google Scholar]

[B17] 17. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med (2012) 367(21):2015–25. doi: 10.1056/NEJMra1009433 [DOI] [PubMed] [Google Scholar]

[B18] 18. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol (2017) 29(11):491–8. doi: 10.1093/intimm/dxx039 [DOI] [PubMed] [Google Scholar]

[B19] 19. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol (2007) 179(8):5571–5. doi: 10.4049/jimmunol.179.8.5571 [DOI] [PubMed] [Google Scholar]

[B20] 20. Maddur MS, Kaveri SV, Bayry J. Circulating normal IgG as stimulator of regulatory T cells: lessons from intravenous immunoglobulin. Trends Immunol (2017) 38(11):789–92. doi: 10.1016/j.it.2017.08.008 [DOI] [PubMed] [Google Scholar]

[B21] 21. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4+ CD25+ Regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood (2008) 111(2):715–22. doi: 10.1182/blood-2007-03-079947 [DOI] [PubMed] [Google Scholar]

[B22] 22. Lories RJ, Casteels-Van Daele M, Ceuppens JL, Van Gool SW. Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro. Ann Rheum Dis (2004) 63(6):747–8. doi: 10.1136/ard.2003.007138 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B23] 23. Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the FC portion and independent of sialylation or basophils. J Immunol (2014) 192(11):5031–8. doi: 10.4049/jimmunol.1301611 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B24] 24. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory FC receptor. Science (2001) 291(5503):484–6. doi: 10.1126/science.291.5503.484 [DOI] [PubMed] [Google Scholar]

[B25] 25. Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN. Dissecting the molecular mechanism of IVIG therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or FC domain. J Mol Biol (2013) 425(8):1253–8. doi: 10.1016/j.jmb.2013.02.006 [DOI] [PubMed] [Google Scholar]

[B26] 26. Jain A, Olsen HS, Vyzasatya R, Burch E, Sakoda Y, Mérigeon EY, et al. Fully recombinant IgG2a Fc multimers (Stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. Arthritis Res Ther (2012) 14(4):R192. doi: 10.1186/ar4024 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B27] 27. Thiruppathi M, Sheng JR, Li L, Prabhakar BS, Meriggioli MN. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun (2014) 52:64–73. doi: 10.1016/j.jaut.2013.12.014 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B28] 28. Zhang X, Owens J, Olsen HS, So E, Burch E, McCroskey MC, et al. A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity. JCI Insight (2019) 4(2):e121905. doi: 10.1172/jci.insight.121905 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B29] 29. Niknami M, Wang MX, Nguyen T, Pollard JD. Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (Experimental autoimmune neuritis). J Peripher Nerv Syst (2013) 18(2):141–52. doi: 10.1111/jns5.12022 [DOI] [PubMed] [Google Scholar]

[B30] 30. Debré M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 342(8877):945–9. doi: 10.1016/0140-6736(93)92000-j [DOI] [PubMed] [Google Scholar]

[B31] 31. Käsermann F, Boerema DJ, Rüegsegger M, Hofmann A, Wymann S, Zuercher AW, et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PloS One (2012) 7(6):e37243. doi: 10.1371/journal.pone.0037243 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B32] 32. Ballow M. Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol (2014) 14(6):509–15. doi: 10.1097/ACI.0000000000000116 [DOI] [PubMed] [Google Scholar]

[B33] 33. Seite J-F, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 7(6):435–9. doi: 10.1016/j.autrev.2008.04.012 [DOI] [PubMed] [Google Scholar]

[B34] 34. Fuchs S, Feferman T, Meidler R, Brenner T, Laub O, Souroujon MC. The disease-specific arm of the therapeutic effect of intravenous immunoglobulin in autoimmune diseases: experimental autoimmune myasthenia gravis as a model. Isr Med Assoc J (2008) 10(1):58–60. [PubMed] [Google Scholar]

[B35] 35. Wallmann J, Pali-Scholl I, Jensen-Jarolim E. Anti-ids in allergy: timeliness of a classic concept. World Allergy Organ J (2010) 3(6):195–201. doi: 10.1097/WOX.0b013e3181e61ebf [DOI] [PMC free article] [PubMed] [Google Scholar]

[B36] 36. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med (2004) 10(1):17–8. doi: 10.1038/nm0104-17 [DOI] [PubMed] [Google Scholar]

[B37] 37. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) (1974) 125C(1-2):373–89. [PubMed] [Google Scholar]

[B38] 38. Lopez-Requena A, Mateo De Acosta C, Vazquez AM, Perez R. Immunogenicity of autologous immunoglobulins: principles and practices. Mol Immunol (2007) 44(11):3076–82. doi: 10.1016/j.molimm.2007.01.005 [DOI] [PubMed] [Google Scholar]

[B39] 39. Schulz R, Werner B, Behn U. Self-tolerance in a minimal model of the idiotypic network. Front Immunol (2014) 5:86. doi: 10.3389/fimmu.2014.00086 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B40] 40. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2002) 20:621–67. doi: 10.1146/annurev.immunol.20.100301.064828 [DOI] [PubMed] [Google Scholar]

[B41] 41. Kedzierska AE, Lorek D, Slawek A, Chelmonska-Soyta A. Tregitopes regulate the tolerogenic immune response and decrease the foetal death rate in abortion-prone mouse matings. Sci Rep (2020) 10(1):10531. doi: 10.1038/s41598-020-66957-z [DOI] [PMC free article] [PubMed] [Google Scholar]

[B42] 42. Massoud AH, Kaufman GN, Xue D, Beland M, Dembele M, Piccirillo CA, et al. Peripherally generated FOXP3(+) regulatory T cells mediate the immunomodulatory effects of IVIg in allergic airways disease. J Immunol (2017) 198(7):2760–71. doi: 10.4049/jimmunol.1502361 [DOI] [PubMed] [Google Scholar]

[B43] 43. Dembele M, Tao S, Massoud AH, Miah SMS, Lelias S, De Groot AS, et al. Tregitopes improve asthma by promoting highly suppressive and antigen-specific Tregs. Front Immunol (2021) 12:634509. doi: 10.3389/fimmu.2021.634509 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B44] 44. Sorde L, Spindeldreher S, Palmer E, Karle A. Massive immune response against IVIg interferes with response against other antigens in mice: a new mode of action? PloS One (2017) 12(10):e0186046. doi: 10.1371/journal.pone.0186046 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B45] 45. Sordé L, Spindeldreher S, Palmer E, Karle A. Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg? Immun Inflammation Dis (2017) 5(4):400–15. doi: 10.1002/iid3.167 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B46] 46. Kwon B, Yang SJ, Cho SM, Kim ME, Nahm DH. Intramuscular administration of autologous total immunoglobulin G induces immunomodulatory effects on T cells in healthy human subjects: An open-labeled prospective single-arm trial. Med (Baltimore) (2022) 101(22):e29486. doi: 10.1097/MD.0000000000029486 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B47] 47. Victor JR, Muniz BP, Fusaro AE, de Brito CA, Taniguchi EF, Duarte AJ, et al. Maternal immunization with ovalbumin prevents neonatal allergy development and up-regulates inhibitory receptor Fc gamma RIIB expression on B cells. BMC Immunol (2010) 11:11. doi: 10.1186/1471-2172-11-11 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B48] 48. Lee SY, Jung YO, Ryu JG, Kang CM, Kim EK, Son HJ, et al. Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner. Arthritis Rheumatol (2014) 66(7):1768–78. doi: 10.1002/art.38627 [DOI] [PubMed] [Google Scholar]

[B49] 49. Ramakrishna C, Newo AN, Shen YW, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PloS Pathog (2011) 7(6):e1002071. doi: 10.1371/journal.ppat.1002071 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B50] 50. Massoud AH, Guay J, Shalaby KH, Bjur E, Ablona A, Chan D, et al. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3–positive regulatory T cells. J Allergy Clin Immunol (2012) 129(6):1656–65. e3. doi: 10.1016/j.jaci.2012.02.050 [DOI] [PubMed] [Google Scholar]

[B51] 51. Othy S, Hegde P, Topçu S, Sharma M, Maddur MS, Lacroix-Desmazes S, et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1–mammalian target of rapamycin axis. J Immunol (2013) 190(9):4535–41. doi: 10.4049/jimmunol.1201965 [DOI] [PubMed] [Google Scholar]

[B52] 52. Victor JR. Do different IgG repertoires play a role in B-and T-cell functional modulation during ontogeny? The “hooks without bait” theory. Immunol Cell Biol (2020) 98(7):540–8. doi: 10.1111/imcb.12335 [DOI] [PubMed] [Google Scholar]

[B53] 53. de Sousa TR, Fagundes BO, Nascimento A, Fernandes LA, Sgnotto FDR, Orfali RL, et al. IgG from adult atopic dermatitis (AD) patients induces thymic IL-22 production and CLA expression on CD4+ T cells: Possible epigenetic implications mediated by miRNA. Int J Mol Sci (2022) 23(12):6867. doi: 10.3390/ijms23126867 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B54] 54. Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood (2013) 122(8):1419–27. doi: 10.1182/blood-2012-11-468264 [DOI] [PubMed] [Google Scholar]

[B55] 55. Massoud AH, Yona M, Xue D, Chouiali F, Alturaihi H, Ablona A, et al. Dendritic cell immunoreceptor: A novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol (2014) 133(3):853–63.e5. doi: 10.1016/j.jaci.2013.09.029 [DOI] [PubMed] [Google Scholar]

[B56] 56. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 27(3):233–45. doi: 10.1007/s10875-007-9088-9 [DOI] [PubMed] [Google Scholar]

[B57] 57. Abbott JK, Chan SK, MacBeth M, Crooks JL, Hancock C, Knight V, et al. Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles. PloS One (2022) 17(3):e0265852. doi: 10.1371/journal.pone.0265852 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B58] 58. Bayry J, Mouthon L, Kaveri SV. Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J Rheumatol (2012) 39(2):450–1. doi: 10.3899/jrheum.111123 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B59] 59. Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-barré syndrome patients. Immunol Res (2014) 60(2-3):320–9. doi: 10.1007/s12026-014-8580-6 [DOI] [PubMed] [Google Scholar]

[B60] 60. Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol (2012) 39(5):1019–25. doi: 10.3899/jrheum.110981 [DOI] [PubMed] [Google Scholar]

[B61] 61. Olivito B, Taddio A, Simonini G, Massai C, Ciullini S, Gambineri E, et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol (2010) 28(1 Suppl 57):93–7. [PubMed] [Google Scholar]

[B62] 62. Jafarzadeh S, Ahmadi M, Dolati S, Aghebati-Maleki L, Eghbal-Fard S, Kamrani A, et al. Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function. J Cell Biochem (2019) 120(4):5424–34. doi: 10.1002/jcb.27821 [DOI] [PubMed] [Google Scholar]

[B63] 63. Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, Aghebati-Maleki L, Dolati S, Farzadi L, et al. Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment. Syst Biol Reprod Med (2017) 63(6):350–9. doi: 10.1080/19396368.2017.1390007 [DOI] [PubMed] [Google Scholar]

[B64] 64. Kasztalska K, Ciebiada M, Cebula-Obrzut B, Gorski P. Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study. Clin Drug Investig (2011) 31(5):299–307. doi: 10.1007/BF03256928 [DOI] [PubMed] [Google Scholar]

[B65] 65. Wang SC, Yang KD, Lin CY, Huang AY, Hsiao CC, Lin MT, et al. Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia. Pediatr Blood Cancer (2020) 67(2):e28075. doi: 10.1002/pbc.28075 [DOI] [PubMed] [Google Scholar]

[B66] 66. Nahm DH, Ye YM, Shin YS, Park HS, Kim ME, Kwon B, et al. Efficacy, safety, and immunomodulatory effect of the intramuscular administration of autologous total immunoglobulin G for atopic dermatitis: A randomized clinical trial. Allergy Asthma Immunol Res (2020) 12(6):949–63. doi: 10.4168/aair.2020.12.6.949 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B67] 67. Nahm DH, Cho SM, Kim ME, Kim YJ, Jeon SY. Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: A preliminary report. Allergy Asthma Immunol Res (2014) 6(1):89–94. doi: 10.4168/aair.2014.6.1.89 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B68] 68. Nahm DH, Kim ME, Cho SM. Effects of intramuscular injection of autologous immunoglobulin on clinical severity and serum IgE concentration in patients with atopic dermatitis. Dermatology (2015) 231(2):145–51. doi: 10.1159/000431173 [DOI] [PubMed] [Google Scholar]

[B69] 69. Nahm DH, Ahn A, Kim ME, Cho SM, Park MJ. Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: long-term changes of clinical severity and laboratory parameters. Allergy Asthma Immunol Res (2016) 8(4):375–82. doi: 10.4168/aair.2016.8.4.375 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B70] 70. Cho SM, Kim ME, Kwon B, Nahm DH. Immunomodulatory effects induced by intramuscular administration of autologous total immunoglobulin G in patients with atopic dermatitis. Int Immunopharmacol (2017) 52:1–6. doi: 10.1016/j.intimp.2017.08.020 [DOI] [PubMed] [Google Scholar]

[B71] 71. Weidinger S, Novak N. Atopic dermatitis. Lancet (2016) 387(10023):1109–22. doi: 10.1016/S0140-6736(15)00149-X [DOI] [PubMed] [Google Scholar]

[B72] 72. Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther (2013) 13(4):549–61. doi: 10.1517/14712598.2013.758708 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B73] 73. Broide DH. Immunomodulation of allergic disease. Annu Rev Med (2009) 60:279–91. doi: 10.1146/annurev.med.60.041807.123524 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B74] 74. Wang FP, Tang XJ, Wei CQ, Xu LR, Mao H, Luo FM. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci (2018) 90(2):190–8. doi: 10.1016/j.jdermsci.2018.01.016 [DOI] [PubMed] [Google Scholar]

[B75] 75. Agache I, Song Y, Posso M, Alonso-Coello P, Rocha C, Sola I, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy (2021) 76(1):45–58. doi: 10.1111/all.14510 [DOI] [PubMed] [Google Scholar]

[B76] 76. Sedeh FB, Henning MAS, Jemec GBE, Ibler KS. Comparative efficacy and safety of monoclonal antibodies and Janus Kinase Inhibitors in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Acta Derm Venereol (2022) 102:adv00764. doi: 10.2340/actadv.v102.2075 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B77] 77. Werfel T. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018. Curr Opin Allergy Clin Immunol (2018) 18(5):432–7. doi: 10.1097/ACI.0000000000000477 [DOI] [PubMed] [Google Scholar]

[B78] 78. Nankervis H, Thomas K, Delamere FM, Barbarot S, Smith S, Rogers NK, et al. What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials. Br J Dermatol (2017) 176(4):910–27. doi: 10.1111/bjd.14999 [DOI] [PubMed] [Google Scholar]

[B79] 79. Agrawal R, Wisniewski JA, Woodfolk JA. The role of regulatory T cells in atopic dermatitis. Curr Probl Dermatol (2011) 41:112–24. doi: 10.1159/000323305 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B80] 80. Samochocki Z, Alifier M, Bodera P, Jeziorkowska R, Rosiak E, Jurkiewicz B, et al. T-regulatory cells in severe atopic dermatitis: alterations related to cytokines and other lymphocyte subpopulations. Arch Dermatol Res (2012) 304(10):795–801. doi: 10.1007/s00403-012-1290-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B81] 81. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy (2013) 68(8):974–82. doi: 10.1111/all.12184 [DOI] [PubMed] [Google Scholar]

[B82] 82. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A who position paper. J Allergy Clin Immunol (1998) 102(4 Pt 1):558–62. doi: 10.1016/s0091-6749(98)70271-4 [DOI] [PubMed] [Google Scholar]

[B83] 83. Berings M, Karaaslan C, Altunbulakli C, Gevaert P, Akdis M, Bachert C, et al. Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol (2017) 140(5):1250–67. doi: 10.1016/j.jaci.2017.08.025 [DOI] [PubMed] [Google Scholar]

[B84] 84. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol (2013) 132(1):110–7. doi: 10.1016/j.jaci.2013.02.044 [DOI] [PubMed] [Google Scholar]

[B85] 85. Yepes-Nunez JJ, Guyatt GH, Gomez-Escobar LG, Perez-Herrera LC, Chu AWL, Ceccaci R, et al. Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol (2023) 151(1):147–58. doi: 10.1016/j.jaci.2022.09.020 [DOI] [PubMed] [Google Scholar]

[B86] 86. Chait I, Allkins V. Remission of life-long atopic dermatitis after hyposensitisation to house dust mite. Practitioner (1985) 229(1405):609–12. [PubMed] [Google Scholar]

[B87] 87. Leroy BP, Lachapelle J-M, Somville M, Jacquemin M, Saint-Remy J. Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis. Dermatology (1991) 182(2):98–106. doi: 10.1159/000247754 [DOI] [PubMed] [Google Scholar]

[B88] 88. Tuft L. Studies in atopic dermatitis: V. Problems in inhalant hyposensitization and results of treatment. J Allergy (1960) 31(1):1–11. doi: 10.1016/0021-8707(60)90019-8 [DOI] [PubMed] [Google Scholar]

[B89] 89. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol (2016) 137(2):358–68. doi: 10.1016/j.jaci.2015.12.1300 [DOI] [PubMed] [Google Scholar]

[B90] 90. Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy–T-cell tolerance and more. Allergy (2006) 61(7):796–807. doi: 10.1111/j.1398-9995.2006.01175.x [DOI] [PubMed] [Google Scholar]

[B91] 91. Matsuda M, Terada T, Kitatani K, Kawata R, Nabe T. Roles of type 1 regulatory T (Tr1) cells in allergen-specific immunotherapy. Front Allergy (2022) 3:981126. doi: 10.3389/falgy.2022.981126 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B92] 92. Hua TC, Hwang CY, Chen YJ, Chu SY, Chen CC, Lee DD, et al. The natural course of early-onset atopic dermatitis in Taiwan: A population-based cohort study. Br J Dermatol (2014) 170(1):130–5. doi: 10.1111/bjd.12603 [DOI] [PubMed] [Google Scholar]

[B93] 93. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol (2017) 139(3S):S1–S46. doi: 10.1016/j.jaci.2016.09.023 [DOI] [PubMed] [Google Scholar]

[B94] 94. Sali AD, Karakasiliotis I, Evangelidou M, Avrameas S, Lymberi P. Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin. Clin Transl Immunol (2015) 4(10):e42. doi: 10.1038/cti.2015.18 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B95] 95. Nawata Y, Koike T, Hosokawa H, Tomioka H, Yoshida S. Anti-IgE autoantibody in patients with atopic dermatitis. J Immunol (1985) 135(1):478–82. doi: 10.4049/jimmunol.135.1.478 [DOI] [PubMed] [Google Scholar]

[B96] 96. Marone G, Casolaro V, Paganelli R, Quinti I. IgG anti-IgE from atopic dermatitis induces mediator release from basophils and mast cells. J Invest Dermatol (1989) 93(2):246–52. doi: 10.1111/1523-1747.ep12277582 [DOI] [PubMed] [Google Scholar]

[B97] 97. Poto R, Patella V, Criscuolo G, Marone G, Coscioni E, Varricchi G. Autoantibodies to IgE can induce the release of proinflammatory and vasoactive mediators from human cardiac mast cells. Clin Exp Med (2022) 23(4):1265–76. doi: 10.1007/s10238-022-00861-w [DOI] [PMC free article] [PubMed] [Google Scholar]

[B98] 98. Poto R, Quinti I, Marone G, Taglialatela M, de Paulis A, Casolaro V, et al. IgG autoantibodies against IgE from atopic dermatitis can induce the release of cytokines and proinflammatory mediators from basophils and mast cells. Front Immunol (2022) 13:880412. doi: 10.3389/fimmu.2022.880412 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B99] 99. Sgnotto FDR, de Oliveira MG, Lira AAL, Inoue AHS, Titz TO, Orfali RL, et al. IgG from atopic dermatitis patients induces IL-17 and IL-10 production in infant intrathymic TCD4 and TCD8 cells. Int J Dermatol (2018) 57(4):434–40. doi: 10.1111/ijd.13907 [DOI] [PubMed] [Google Scholar]

[B100] 100. Santos LS, Sgnotto FDR, Sousa TR, Orfali RL, Aoki V, Duarte AJDS, et al. IgG from atopic dermatitis patients induces non-atopic infant thymic invariant natural killer T (iNKT) cells to produce IL-4, IL-17, and IL-10. Int J Dermatol (2019) 59(3):359–64. doi: 10.1111/ijd.14688 [DOI] [PubMed] [Google Scholar]

[B101] 101. Mikus M, Johansson C, Acevedo N, Nilsson P, Scheynius A. The antimicrobial protein S100A12 identified as a potential autoantigen in a subgroup of atopic dermatitis patients. Clin Transl Allergy (2019) 9:6. doi: 10.1186/s13601-019-0240-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B102] 102. Fagundes BO, de Sousa TR, Nascimento A, Fernandes LA, Sgnotto FDR, Orfali RL, et al. IgG from adult atopic dermatitis (AD) patients induces nonatopic neonatal thymic gamma-delta T cells (ΓδT) to acquire IL-22/IL-17 secretion profile with skin-homing properties and epigenetic implications mediated by miRNA. Int J Mol Sci (2022) 23(12):6872. doi: 10.3390/ijms23126872 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance

Jefferson Russo Victor

Dong-Ho Nahm

Abstract

1. Introduction

1.1. Immune tolerance and regulatory T cells

1.2. Polyvalent immunoglobulin G for immune regulation

1.3. Idiotypic network theory

1.4. Anti-idiotypic regulatory T cell theory for immune tolerance

2. Four hypothetical models for the mechanism underlying polyvalent IgG-induced activation of Treg cells

Figure 1.

Table 1.

2.1. Hypothetical model 1 and 2: activation of Treg cells by peptides from polyvalent IgG processed by APCs (main hypotheses of authors)

Table 2.

2.2. Hypothetical model 3 and 4: activation of Treg cells by direct binding of polyvalent IgG to surface receptors on T cells or APCs

3. Evidence supporting activation of Treg cells by polyvalent IgG in clinical trials

3.1. Evidence supporting activation of Treg cells upon intravenous administration of IVIg in human clinical trials

Table 3.

3.2. Clinical application of “active anti-idiotypic therapy” with polyvalent IgG: lessons obtained from clinical trials on intramuscular injection of autologous total IgG in patients with atopic dermatitis

3.2.1. Current knowledge on pathogenesis and treatment of atopic dermatitis

3.2.2. Critical role of decreased number and/or function of Treg cells in the pathogenesis of atopic dermatitis

3.2.3. Immunomodulatory therapies that induced a long-term treatment-free clinical remission in patients with atopic dermatitis

3.2.3.1. Allergen immunotherapy

3.2.3.2. Natural remission of disease in children with atopic dermatitis

3.2.3.3. Intramuscular administration of autologous polyvalent IgG for induction of anti-idiotype immune modulation

Table 4.

3.2.3.4. Comparison of efficacy and mechanism of intravenous injection of heterologous polyvalent IgG and intramuscular injection of autologous total IgG in patients with atopic dermatitis

3.3. In vitro and animal studies about IgG-mediated anti-idiotypic immuno-modulation: lessons from experiments using IgG from donors with various immune backgrounds

3.3.1. Immunomodulatory effects induced by polyvalent IgG from donors with various immune backgrounds

3.3.2. Experimental observations regarding IgG from patients with atopic dermatitis

4. Six questions on the mechanism underlying polyvalent IgG-induced activation of Treg cells and its clinical application for the treatment of immune diseases

Box 1. A new concept of active anti-idiotypic therapy with autologous polyvalent IgG for allergic and autoimmune diseases.

5. Future research directions (research topics) involving the mechanism and clinical application of polyvalent IgG-induced activation of Treg cells

6. Conclusion

Author contributions

Acknowledgments

Funding Statement

Conflict of interest

Publisher’s note

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases